Vitro Biopharma Files New Patents for Stem Cell Therapy of Neurological Conditions

GOLDEN, CO / ACCESSWIRE / November 7, 2016 / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced the filing of four new patent applications at the United States Patent Office seeking protection of its proprietary stem cell products and technology related to treatment of neurological conditions. The new patents cover technology related to activation of stem cells within the brain as well as unique combinations of stem cell transplants together with stem cell activation. The neurological conditions include traumatic brain injury (TBI), Parkinson's disease, Alzheimer's disease, stroke, autism, Lou Gehrig's Disease, and other neurodegenerative diseases. Many of these conditions have limited treatment options, while stem cell therapy has support from early clinical studies showing safety and efficacy in the treatment of stroke. The Company plans to focus its initial efforts on TBI & autism through strategic partners with complementary assets. We also have clinical protocols for TBI and a prior grant of exemption from IND filing by the FDA Division of Neurological products for TBI trials based on pharmaceutical activation of stem cells in the brain. Our development plans involve establishing IRB-regulated clinical trials at initial centers while also expanding the network of centers participating in these trials.

Dr. Jim Musick, President & CEO of Vitro Biopharma said, "We are very pleased to announce the filing of these additional patents that expand our proprietary position to include stem cell transplants followed by stem cell activation or differentiation using a combination of generic drugs at specific dosages or nutraceuticals either alone or in certain combinations. We now support ongoing offshore clinical trials of osteoarthritis (OA) through stem cell expansion in our clinical grade cell culture medium, MSC-Gro. These phase I results show short-term reduction in pain and long-term restoration of function and cartilage regeneration in patients with OA of the knee, hip and shoulder. We are developing other similar partnerships. Our newly filed patents include the activating pharmaceutical and nutraceuticals agents that induce stem cell activation, diagnostic testing of stem cell status and stem cell regenerative effects through biomarker profiling, and treatment of stem cells by exposure to activating agents prior to transplantation. The latter patent includes a proprietary epigenetic protocol for the treatment of autism that is supported by preliminary studies conducted by Dr. Josef Smarda & colleagues in Eastern Europe. The addition of specific neural stem cell differentiation directing stem cells into dopaminergic neurons is now being developed by Vitro Biopharma's team of R&D scientists for the treatment of Parkinson's disease."

About Vitro Biopharma

Vitro Biopharma's (http://www.vitrobiopharma.com/) mission is "Harnessing the Power of Cells™" for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern, GMP-compliant biotechnology manufacturing and R&D facility in Golden, Colorado. Vitro Biopharma manufactures and sells "Tools for Stem Cell and Drug Development™", including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for MSC self-renewal and lineage-specific differentiation. Our cell lines include cancer-associated fibroblasts (CAFs) derived from lung, colorectal, ovarian, uterine, pancreatic and breast tumors. These cell lines are being widely used by pharmaceutical/biotechnology firms as drug discovery tools in the full development of cancer immunotherapy, especially for solid tumors. We also provide optimized primary cell culture medium, Vitro-Plus III™ Medium, for growth of our CAF cell lines. In addition, we provide MSC-derived progenitor cells, including neural stem cells (NSCs), nephron progenitor cells (NPCs) as well as a growing line of terminally differentiated cells: cholinergic, dopaminergic and sensory neurons, osteoblasts, chondrocytes, cardiomyocytes, and renal tubular epithelial cells. A primary application of these terminally differentiated cells is cell-based assays for drug discovery and pre-clinical toxicology of drugs, drug candidates and drug combinations that may produce toxic effects on cardiac, neural or renal cells, either directly or through metabolites derived from the interaction of drugs with specific cells such as liver cells. Vitro Biopharma now provides its Clinical Grade MSC-Gro™ Media for expansion of stem cells prior to transplantation for clinical studies of osteoarthritis treatment and products for use in preliminary studies of stem cell activation therapy for ASD & autoimmunity.

Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.

Safe Harbor Statement

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

SOURCE: Vitro Biopharma